Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
01/04/2026 04:00 PM • Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
CRNX - The company is announcing progress on its lead commercialized product PALSONIFY and providing results from an advanced-stage clinical trial (Phase 2 fourth cohort) for atumelnant, indicating continued pipeline advancement and commercial execution. The announcement of a pivotal Phase 3 trial initiation (mentioned in the article) further demonstrates positive momentum in drug development.